Necrotic Enteritis (NE) Treatment Market

By Type;

Oral and Parenteral

By Drug Class;

Inter-Alpha-Inhibitor-Proteins ("IaIp"), Antibiotics, and Dietary Supplements

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn139443257 Published Date: August, 2025

Necrotic Enteritis Treatment Market Overview

Necrotic Enteritis Treatment Market (USD Million)

Necrotic Enteritis Treatment Market was valued at USD 28,201.31 million in the year 2024. The size of this market is expected to increase to USD 44,872.00 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.9%.


Necrotic Enteritis (NE) Treatment Market

*Market size in USD million

CAGR 6.9 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.9 %
Market Size (2024)USD 28,201.31 Million
Market Size (2031)USD 44,872.00 Million
Market ConcentrationMedium
Report Pages340
28,201.31
2024
44,872.00
2031

Major Players

  • Prometic Life Sciences Inc
  • BioGaia Probiotics
  • Fresenius Kabi AG
  • Actavis Plc
  • Bayer International

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Necrotic Enteritis (NE) Treatment Market

Fragmented - Highly competitive market without dominant players


The Necrotic Enteritis Treatment Market is witnessing notable growth as poultry farms respond to rising disease incidence, with treatment adoption increasing by over 40%. This condition significantly impacts broiler production, leading to major economic losses. Companies are implementing effective strategies that focus on enhancing gut health through antibiotics, probiotics, and vaccines. Strong collaboration between animal health innovators and commercial poultry producers is supporting continuous expansion of treatment usage.

Industry Alliances Supporting Broader Clinical Adoption
An increase of over 38% in collaborative efforts between veterinary scientists, integrators, and biotech companies has streamlined the validation of new therapies. These strategic collaborations are enabling more rapid clinical integration and simplifying regulatory pathways. Recent mergers among leading firms are enhancing product access and strengthening disease prevention frameworks. These alliances are creating a stronger base for market expansion.

Usage Expanding Across Large-Scale Poultry Operations
Adoption of necrotic enteritis treatments has risen by more than 42% across broiler farms and breeder operations. New formulations are being integrated into routine feed and water management systems. Companies are executing targeted growth strategies including educational campaigns and bundled veterinary solutions. Broader partnerships with commercial farms and integrators are further supporting consistent expansion of treatment protocols across large flocks.

Future Outlook Focused on Sustainable and Preventive Approaches
Over 44% of companies are shifting their pipeline toward probiotic, phytogenic, and phage-based solutions, reflecting a clear move away from conventional antimicrobials. These changes are shaping the market’s future outlook as regulatory preferences evolve. Continued innovation in microbiome science and data-driven livestock health management is creating long-term value. Firms are adopting expansion strategies that emphasize sustainability, precision farming, and antibiotic stewardship in poultry care.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Drug Class
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Necrotic Enteritis Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising disease prevalence
        2. Advancements in pharmaceuticals
        3. Improved diagnostic techniques
        4. Growing poultry industry
        5. Increased R&D investments
      2. Restraints
        1. High treatment costs
        2. Regulatory approval delays
        3. Limited treatment options
        4. Lack of awareness
        5. Economic instability impacts
      3. Opportunities
        1. Emerging market expansion
        2. New drug development
        3. Advanced treatment research
        4. Strategic partnerships formation
        5. Veterinary education programs
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Necrotic Enteritis Treatment Market, By Type, 2021 - 2031 (USD Million)
      1. Oral

      2. Parenteral

    2. Necrotic Enteritis Treatment Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Inter-Alpha-Inhibitor-Proteins ("IaIp")
      2. Antibiotics
      3. Dietary Supplements
    3. Necrotic Enteritis Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Drug Stores
    4. Necrotic Enteritis Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa

        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Prometic Life Sciences Inc [Canada]
      2. BioGaia Probiotics [Sweden]
      3. Fresenius Kabi AG [Germany]
      4. Actavis Plc [Ireland]
      5. Bayer International [Germany]
  7. Analyst Views
  8. Future Outlook of the Market